CN-121987625-A - Use of ergothioneine in promoting recovery of nerve function after spinal cord injury

Abstract

The invention discloses application of ergothioneine in promoting nerve function recovery after spinal cord injury. New uses of ergothioneine include inhibiting tissue or cell aging in the central nervous system following spinal cord injury, treating glial cell mitochondrial dysfunction following spinal cord injury, promoting spinal cord injury repair, and inhibiting spinal cord tissue inflammation following spinal cord injury. The invention reveals that ergothioneine can obviously promote spinal nerve regeneration, improve nerve function, reduce inflammatory reaction after aging and protect spinal tissues by regulating and controlling the mitochondrial function of immune cells and the cell aging axis for the first time, thereby providing an innovative strategy for spinal cord injury treatment. Ergothioneine intervenes in the secondary neurodegenerative disease after spinal cord injury by protecting mitochondrial function and immune double-channel synergy, and provides a brand new direction for SCI treatment.

Inventors

• Qian Zhanchang
• XU GUANHUA
• ZHOU JIAN
• XIA MINGJIE
• ZHANG YANAN
• CUI ZHIMING

Assignees

• 南通市第一人民医院

Dates

Publication Date

20260508

Application Date

20260304

Claims (10)

1. 1. Use of ergothioneine in the preparation of a medicament for inhibiting tissue or cell senescence in the central nervous system following spinal cord injury.
2. 2. The use according to claim 1, wherein the tissue is spinal cord tissue and the cells are glial cells.
3. 3. The use according to claim 2, wherein the glial cells are microglia.
4. 4. Application of ergothioneine in preparing medicine for treating mitochondrial dysfunction of glial cells after spinal cord injury is provided.
5. 5. The use according to claim 4, wherein the glial cells are microglial cells in spinal cord tissue.
6. 6. Application of ergothioneine in preparing medicine for promoting spinal cord injury repair is provided.
7. 7. The application of ergothioneine in preparing medicines for inhibiting spinal tissue inflammation after spinal cord injury.
8. 8. The use according to claim 7, wherein the inflammation is an inflammation caused by aging of spinal cord tissue.
9. 9. The use according to any one of claims 1-8, wherein the spinal cord injury comprises spinal cord injury-related neurological dysfunction and/or spinal cord injury-related peripheral nerve injury and nerve conduction disorder.
10. 10. A spinal cord injury postaging inhibitor containing ergothioneine is provided.

Description

Use of ergothioneine in promoting recovery of nerve function after spinal cord injury Technical Field The invention relates to a medicament for repairing spinal cord injury and resisting aging, in particular to application of ergothioneine in promoting nerve function recovery after spinal cord injury. Background Spinal cord injury (Spinalcordinjury, SCI) is a traumatic disorder of the central nervous system that can lead to severe nerve tissue damage and nerve dysfunction. Pathophysiological processes of spinal cord injury include primary and secondary injury involving a variety of pathological mechanisms such as oxidative stress, inflammation, autophagy, iron death, and mitochondrial dysfunction. The primary injury mainly refers to neuron axon fracture, spinal cord hemorrhage and blood-spinal cord barrier destruction caused by external force, and the secondary injury mainly comprises persistent inflammatory reaction, and is accompanied with changes such as apoptosis, glial scar formation, mitochondrial dysfunction and the like, so that the nerve function is further deteriorated. Studies have shown that a large number of oxidative and inflammatory factors can be released after spinal cord injury, and originally presented as anti-inflammatory and pro-prosthetic M2-like microglial cells are de-polarized into pro-inflammatory and pro-injured M1-like microglial cells, amplifying local inflammatory responses, exacerbating nerve tissue injury and dysfunction. At present, the clinical treatment is mainly performed by operation decompression, glucocorticoid impact and rehabilitation training, but the clinical treatment still has a plurality of limitations: (1) The traditional glucocorticoid is difficult to specifically inhibit inflammatory factors related to microglial oxidative stress, and is easy to induce infection after long-term use; (2) Antioxidant effect is limited in that existing antioxidants such as Edaravone mainly act by scavenging ROS and cannot significantly improve mitochondrial function; (3) Nerve regeneration disorders neurotrophic factors such as BDNF are difficult to deliver effectively under the scar barrier. Ergothioneine (Ergothioneine, EGT) is a naturally occurring amino acid having the structural formula: Clinical data show that ergothioneine has a 14-fold capacity to scavenge free radicals compared to glutathione and 30-fold capacity to coenzyme Q10. Ergothioneine has a proprietary transporter OCTN-1, and the transporter OCTN-1 is also present in large amounts in the spinal cord, with good nervous system penetration and biosafety. The molecule exhibits significant protective effects in multiple models of neurodegenerative diseases. The mechanism of action of ergothioneine shown in the prior studies jie includes: neuroprotection by EGT inhibiting alpha syn aggregation, restoring neuronal loss and behavioral disorders; mitochondrial targeting, namely, EGT can penetrate through the blood brain barrier, be enriched in the online granulocytes and directly regulate and control mitochondrial functions; Immunomodulatory ability EGT can modulate macrophage polarization state. However, there is currently no systematic study that reveals the mechanism of action of ergothioneine in targeting microglial aging following spinal cord injury, particularly in the modulation of microglial aging and secondary inflammation by mitochondria. Disclosure of Invention The invention aims to provide application of ergothioneine in preparing a medicament for inhibiting tissue or cell aging in the central nervous system after spinal cord injury, and solve the problem of inhibiting tissue or cell aging in the central nervous system after spinal cord injury. A second object of the present invention is to propose the application of ergothioneine in preparing a medicament for treating mitochondrial dysfunction of glial cells after spinal cord injury, which solves the problem of how to treat mitochondrial dysfunction of glial cells after spinal cord injury. The third purpose of the invention is to provide application of ergothioneine in preparing a medicament for promoting spinal cord injury repair, so as to solve the problem of how to promote spinal cord injury repair. The fourth aim of the invention is to provide the application of ergothioneine in preparing the medicines for inhibiting spinal cord tissue inflammation after spinal cord injury, and solve the problem of how to inhibit spinal cord tissue inflammation after spinal cord injury. A fifth object of the present invention is to propose an inhibitor of post-spinal cord injury aging comprising ergothioneine. The invention firstly discloses application of ergothioneine in preparing a medicament for inhibiting tissue or cell aging in a central nervous system after spinal cord injury. Preferably, the tissue is spinal cord tissue and the cells are glial cells. Preferably, the glial cell is a microglial cell. The second aspect of the invention discloses the use of ergothio